Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

  • Overview
  • Find a Doctor
  • Latest Advances
  • Clinical Trials
  • Treatments
Match to trials
Find the right clinical trials for you in under a minute
Get started

Customize your search results with filters

Phase
    Intervention Type
      Status
        Location:
        Radius:
          Term Search
          You can select from the dropdown list OR enter your own terms to refine the search.

          Last Updated: 02/19/2023

          Need to find the closest trial?
          Sort By Distance
          Save trials for later
          Sign Up
          Not sure about your diagnosis?
          Check Your Symptoms
          Tired of the same old research?
          Check Latest Advances
          Newest Clinical Trials
          231 Clinical Trials
          Sort By

            Foundation Fighting Blindness My Retina Tracker Registry

            Enrollment Status: Recruiting
            Publish Date: February 15, 2023

            Summary: The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on the...

            Fresh Corneal Lenticule Implantation in Macular Corneal Distrophy With Relex-Smile Surgery

            Who is this study for: Patients with Macular Corneal Dystrophy
            Enrollment Status: Enrolling by invitation
            Publish Date: February 15, 2023
            Intervention Type: Procedure
            Study Phase: Not Applicable

            Summary: The aim of the study is to examine the effect of fresh corneal lenticule implantation as allogenic graft taken from myopic patients to implanted in patients with macular corneal dystrophy using Visumax Femtosecond Laser Smile module surgery.

            A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

            Enrollment Status: Recruiting
            Publish Date: February 14, 2023
            Intervention Type: Drug
            Study Phase: Phase 2

            Summary: This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.

            Vitrectomy, Subretinal Tissue Plasminogen Activator and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative Age-Related Macular Degeneration (TIGER): a Phase 3, Pan-European, Two-group, Observer-masked, Superiority, Randomised Controlled Surgical Trial.

            Who is this study for: Patients with submacular hemorrhage secondary to exudative age-related macular degeneration
            Enrollment Status: Recruiting
            Publish Date: February 14, 2023
            Intervention Type: Drug, Procedure
            Study Drugs: AfliberceptAlteplaseSulfahexafluoride gas tamponade
            Study Phase: Phase 3

            Summary: The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces. These cells can be damaged by a disease called wet age-related macular degeneration (AMD), where new abnormal blood vessels grow through the macula and leak fluid. This can affect vision. In some cases, wet AMD can also cause a bleed under the macul...

            Effectiveness of Brolucizumab in Pretreated Patients With nAMD in the Real-world Setting in Gulf Countries United Arab of Emirates, Kuwait , Bahrain , Oman and Qatar

            Enrollment Status: Recruiting
            Publish Date: February 14, 2023
            Intervention Type: Other

            Summary: The study is a prospective and retrospective, observational, single-arm, non-randomized cohort study of ocular treatment with intravitreal injections of brolucizumab in nAMD patients. This study will be conducted prospectively and retrospectively (for patients who had their first brolucizumab injection before study start) using data collected in a standardized manner.

            A Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RC28-E 2mg Versus Aflibercept in Subjects With Wet Age-Related Macular Degeneration

            Enrollment Status: Recruiting
            Publish Date: February 14, 2023
            Intervention Type: Drug
            Study Phase: Phase 3

            Summary: This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

            A Two Stage Phase 2 Study: Stage 1: Single Subcutaneous Dose Open-label Assessment of Safety and Pharmacodynamic Response to D-4517.2 (Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)

            Enrollment Status: Recruiting
            Publish Date: February 13, 2023
            Intervention Type: Drug
            Study Phase: Phase 2

            Summary: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)

            Rod and Cone Mediated Function in Retinal Disease

            Enrollment Status: Recruiting
            Publish Date: February 10, 2023

            Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease.

            A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration

            Who is this study for: Patients with Age Related Macular Degeneration
            Enrollment Status: Recruiting
            Publish Date: February 10, 2023
            Intervention Type: Drug
            Study Drugs: ASP7317Tacrolimus
            Study Phase: Phase 1

            Summary: This study is for adults 50 years or older who are losing their clear, sharp central vision. Central vision is needed to be able to read and drive a car. They have been diagnosed with dry age-related macular degeneration (called dry AMD). The macula is the center part of the back of the eye that allows you to see fine detail. In an advanced stage of this disease, areas of the macula die (atrophy),...

            Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective Study

            Enrollment Status: Recruiting
            Publish Date: February 09, 2023
            Intervention Type: Drug
            Study Phase: Phase 4

            Summary: The investigator propose to conduct a randomized clinical trial, investigating the safety and efficacy of brolucizumab for treatment of nAMD patients with CNV, and plans to specifically target those who are not responding to standard Treat and Extend (T&E) treatment. A randomised omized study will be conducted with 2 arms, one with the new drug (brolocizumab) and novel treatment protocol versus a ...

            Targeted Fluorescence Imaging Using Bevacizumab-800CW Within Age-related Macular Degeneration (AMD) Patients to Evaluate the Upregulation of VEGF

            Enrollment Status: Recruiting
            Publish Date: February 09, 2023
            Intervention Type: Drug
            Study Phase: Phase 1

            Objective: To determine the safety and feasibility of fluorescence imaging of the eye with the fluorescent tracer bevacizumab-800CW for identification AMD with scanning laser angiography Study design: A non-randomized, non-blinded, prospective, single-center feasibility study. Study population: Patients group: patients with naïve wet AMD and wet AMD aged >60 years old with current treatment of anti-VEGF intr...

            A Multicenter, Randomized, Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular Degeneration

            Enrollment Status: Recruiting
            Publish Date: February 08, 2023
            Intervention Type: Drug
            Study Phase: Phase 3

            Summary: A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental group and control group in a 1:1 ratio, and stratified randomized according to the letter value of baseline period and w...

            Showing 1-12 of 231

            Last Updated: 02/19/2023

            Better Care. Faster.
            • How MediFind Works
            • Our Story
            • Conditions A-Z
            • Doctor Directory
            • Symptoms Directory
            • Procedures Directory
            • Newsroom
            • Partnering With Us
            • Contact Us
            Subscribe to our newsletter

            Sign up to stay informed about MediFind and get wellness sent your way.

            By subscribing, I agree to MediFind's Terms & Conditions and Privacy Policy.

            • FAQ
            • Feedback
            • Advertising Policy
            • Privacy Policy
            • Terms & Conditions
            Follow Us On
            MediFindBetter Care. Faster.
            © 2023 All Rights Reserved.

            This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.